Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Psoriasis
Recruiting2 awardsPhase 3
Monroe, Louisiana
This trial will study the long-term safety and effectiveness of the drug Deucravacitinib in people who have previously taken it for psoriasis in a different trial.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.